Latest Headlines

Latest Headlines

Private equity looks for $905M in sale of Japan's Showa

Looking for a local beachhead in Japan? Private equity firm Tokio Marine Capital is looking to sell the drugmaker Showa Yakuhin Kako in a deal that could bring in as much as $905 million, sources

Pfizer, Roche, Novartis lead the way in Japan

As Japanese drugmakers look outside their home market for acquisitions and growth, Big Pharma is moving in. With sales growth slowing to a crawl in the U.S. and Europe, global drugmakers have...

Japanese clear Novartis' Gilenya, Vertex's hep C drug

Japanese regulators approved two important new drugs: Novartis's Gilenya, the first oral multiple sclerosis treatment, and Vertex Pharmaceuticals's Telavic, the hepatitis C treatment sold as Incivek

Teva takes over Japanese JV, eyes $1B in sales

Aiming to boost its Japanese sales to $1 billion, Teva Pharmaceutical Industries ($TEVA) has bought out its joint venture partner there. The Israeli drugmaker paid $150 million in cash for Kowa's 50%

Takeda parlays Baxter's vax methods into Japanese subsidies

Takeda Pharmaceutical ($TKPHF) has scored again with its home government, this time winning a ¥23.9 billion ($311 million) subsidy to develop an advanced commercial production facility for new

Japan asks Boehringer to warn docs on Pradaxa

One anticipated risk of Boehringer Ingelheim's new blood thinner Pradaxa has led to an unexpected warning. Japanese regulators have asked the German company to notify doctors about potentially deadly

Fujifilm teams with Dr Reddy's on Japanese generics

Fujifilm said it wanted to expand further into the pharma business, and now it has. The Japanese conglomerate has set up a new joint venture with Indian generics maker Dr Reddy's. The two companies

Pfizer's Lyrica performs in Japanese fibromyalgia trial

Pfizer has racked up some positive data for Lyrica in Japan. A new study found that fibromyalgia patients saw a statistically significant reduction in their mean pain score after treatment with

Japan ushers in big meds from AZ, GSK, Merck

Japanese health regulators spread some happiness yesterday, granting marketing approval to several major Big Pharma products. AstraZeneca, GlaxoSmithKline, and Merck each got the nod for a key drug

For Japanese M&A, integration's the key

Japan has about 2,400 drug manufacturers. Sounds like an industry ripe for consolidation? But Japanese drugmakers with the resources to snap up smaller companies don't want domestic buyouts. They're